Hydrochlorothiazide (HCTZ)
Hydrochlorothiazide
Version 2025-04 · Last reviewed April 1, 2025 · Methodology
List Price
$5–20 (generic only)
With Insurance
$3–10
The Short Version
Evidence summary
Hydrochlorothiazide (HCTZ) (Hydrochlorothiazide) is a Thiazide Diuretic prescribed for Hypertension (first-line per JNC/ALLHAT) and Edema (mild). FDA-approved in January 1959.
The most commonly reported side effects are Increased urination (15–20%), Hypokalemia (low potassium) (10–15%), Dizziness / lightheadedness (8%). Expected mechanism — take in the morning to avoid nighttime bathroom trips
Most research was funded by the manufacturer — independent replication is limited.
What This Really Costs
Long-term cost projection based on current pricing
Monthly
$13
$7 w/ insurance
without insurance
Annual
$156
$84 w/ insurance
without insurance
10 Years
$1.6K
$840 w/ insurance
without insurance
30 Years
$4.7K
$2.5K w/ insurance
without insurance
Lifestyle alternative: $0/month in prescriptions. DASH Diet — Reduces systolic BP 8–14 mmHg — comparable to a single antihypertensive medication.
The average American retiree spends $165,000 on healthcare over their lifetime (Fidelity, 2024). Informed choices today compound over decades.
CMS MAHA ELEVATE
This medication has lifestyle alternatives supported by evidence
See how EvidentMeds supports the CMS MAHA ELEVATE program for clinicians
Quick Answers
Now what?
You've read the evidence. Here are your next steps.
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Metabolic & Lifestyle Alternatives
Blood Pressure Reduction: Addressing the Lifestyle Drivers of Hypertension
HCTZ lowers blood pressure by reducing blood volume — it does not address why blood pressure is elevated. The primary modifiable drivers of hypertension are excess sodium intake, obesity (especially visceral fat), physical inactivity, excessive alcohol, chronic stress, and poor sleep. Lifestyle interventions addressing these factors can reduce blood pressure by amounts comparable to or exceeding a single medication.
Important context: Evidence quality varies across these approaches. Some are well-studied with randomized controlled trial data; others are based on observational or smaller studies. These interventions are not guaranteed to replace medication for all patients. Discuss with your doctor whether any of these are appropriate for your clinical situation.
DASH Diet
Specifically designed and proven to lower blood pressure through a combination of reduced sodium, increased potassium, and whole-food nutrients
Reduces systolic BP 8–14 mmHg — comparable to a single antihypertensive medication. When combined with sodium restriction (<1500mg/day), reductions reach 11–20 mmHg.
Sodium Restriction (<2000mg/day)
Excess sodium is the single largest dietary contributor to hypertension in most populations
Reduces systolic BP 5–10 mmHg; effect is additive with DASH diet and exercise. SSaSS trial (2021): salt substitution reduced CV events 14%.
Aerobic Exercise (150 min/week)
Regular exercise improves endothelial function, reduces arterial stiffness, and lowers resting sympathetic tone
Meta-analyses show aerobic exercise reduces systolic BP 5–8 mmHg; resistance training adds 2–3 mmHg reduction. Comparable to HCTZ at low doses.
Weight Loss 5–10% Body Weight
Every 1kg of weight loss reduces systolic BP ~1 mmHg; visceral fat loss is particularly impactful
10% body weight loss can reduce systolic BP 5–10 mmHg, often enough to eliminate need for one antihypertensive medication.
Alcohol Reduction
More than 2 drinks/day significantly elevates blood pressure; reduction produces measurable improvement within weeks
Reducing from heavy drinking to moderate reduces systolic BP 4–8 mmHg; complete abstinence provides additional benefit.
Key Studies
Global Prescribing & Pricing
HCTZ is prescribed worldwide — it represents what happens when a cheap, effective drug exists but generates no profit for anyone to promote it
United States
$5–20/mo
Despite ALLHAT evidence, often bypassed in favor of more expensive ARBs, CCBs, and ACE inhibitors
ALLHAT showed thiazides are first-line — yet prescribing patterns favor branded, more expensive drugs. No one markets HCTZ because there is no profit in it.
Universally covered; one of the cheapest medications available
United Kingdom
~$2–5/mo
NICE recommends thiazide-like diuretics (indapamide preferred) as first-line alongside CCBs
Cost-effectiveness valued; thiazide-type diuretics appropriately positioned as first-line
NHS covered
Germany
~$3–8/mo
Standard first-line per European guidelines
Low cost means appropriate utilization without economic barriers
GKV covered
Australia
~$3–6 (PBS)/mo
PBS listed as first-line antihypertensive
Appropriately positioned as first-line based on evidence
PBS covered; minimal cost
HCTZ/thiazide diuretics are the inverse of the usual pharmaceutical pricing problem. They are cheap, effective, and evidence-based — which means no company has an incentive to promote them. ALLHAT proved a $5/month generic was as good as drugs costing $150–600/month. The result? ALLHAT's findings were systematically downplayed by industry-funded opinion leaders, and prescribing shifted toward expensive branded alternatives with no superior outcomes.
Clinical Trials & Funding
Understanding who funds research helps contextualize results. Industry-funded trials are not automatically invalid — they undergo the same FDA review — but declared conflicts and sponsor effects are worth knowing. All linked trials can be verified on ClinicalTrials.gov.
Funding Sources
Uniquely among commonly prescribed cardiovascular medications, the most important HCTZ-class trials were publicly funded. ALLHAT — the largest antihypertensive trial ever conducted (42,000+ patients) — was funded by NHLBI (National Heart, Lung, and Blood Institute). It found that the thiazide diuretic chlorthalidone was as good as or better than more expensive calcium channel blockers and ACE inhibitors for preventing cardiovascular events. This was profoundly inconvenient for pharmaceutical companies selling expensive branded alternatives.
Declared Conflicts of Interest
ALLHAT's conclusion that a cheap, generic diuretic was first-line therapy threatened billions in branded antihypertensive sales. Industry-funded trials subsequently promoted ACE inhibitors, ARBs, and calcium channel blockers as superior — despite ALLHAT showing comparable or inferior outcomes at 10–50× the cost. The prescribing shift toward expensive branded drugs despite ALLHAT evidence is one of the clearest examples of marketing overriding evidence in medicine.
Key Efficacy Results
Reduces systolic BP 10–15 mmHg; ALLHAT showed thiazide-type diuretics prevent CV events as well as or better than newer, more expensive drug classes; 36% stroke reduction in SHEP
Referenced Studies
Each study carries a Cochrane RoB-2 risk-of-bias badge — tap the badge for details.
Evidence & Transparency
Cochrane RoB-2 (Risk of Bias)
Badges reflect an editorial assessment using Cochrane's RoB-2 tool domains: randomization, intervention deviation, missing data, outcome measurement, and selective reporting. These are not certified Cochrane reviews. Learn more ↗
CMS Open Payments
Manufacturer payment disclosures are reported via the CMS Sunshine Act. Disclosure is legally required and does not imply bias or misconduct. Language uses "may," "suggests," or "appears" — never definitive clinical claims. CMS Open Payments ↗
Live Clinical Trials
Live from ClinicalTrials.gov · refreshed every 4 hours
Currently enrolling, active, and recently completed studies involving Hydrochlorothiazide. Data is pulled directly from the U.S. National Library of Medicine.
Recent Research
Live from PubMed · peer-reviewed literature · refreshed every 4 hours
Most recently indexed clinical trials and systematic reviews mentioning Hydrochlorothiazide in PubMed.
Source Documentation
Structured citations for referenced clinical trials
Each referenced trial is listed with its registry ID, funding source, and bias assessment. Use the copy button to generate a formatted citation.
| Trial | Registry ID | Cite |
|---|---|---|
| ALLHAT (NHLBI-Funded) | PMID:12479763 | |
| SHEP Trial (NIA/NHLBI) | PMID:1992832 | |
| JNC 7 Guidelines | PMID:14656957 |
Bias ratings use Cochrane RoB-2 methodology. Editorial assessment — not a certified Cochrane review.
Our MethodologyMedical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Common Side Effects
While taking this medication, you may experience the following common side effects. We've included tips on how to manage them.
Increased urination
15–20%Expected mechanism — take in the morning to avoid nighttime bathroom trips
Dizziness / lightheadedness
8%Rise slowly from sitting/lying; stay hydrated; especially common during first weeks
Hypokalemia (low potassium)
10–15%Eat potassium-rich foods; prescriber may add potassium supplement or switch to potassium-sparing combination
Increased blood sugar
5–10%Monitor glucose if diabetic or pre-diabetic; this effect can worsen insulin resistance over time
Elevated uric acid / gout
5–8%HCTZ reduces uric acid excretion; may trigger gout attacks in susceptible individuals
Serious Adverse Effects
- • Severe hypokalemia — can cause dangerous cardiac arrhythmias; monitor potassium regularly
- • Hyponatremia (low sodium) — especially dangerous in elderly; can cause confusion, seizures, falls
- • Acute kidney injury — usually from dehydration or combination with NSAIDs
- • Photosensitivity — increased skin cancer risk with long-term use (FDA added warning)
- • Sulfonamide cross-reactivity — rare severe allergic reactions in sulfa-allergic patients
Drug Interactions
Major Interactions (Avoid)
Moderate Interactions (Caution)
Food Interactions
When to Contact Your Doctor
This medication requires ongoing medical supervision. The following situations warrant a prompt conversation with your prescribing physician — do not wait for your next scheduled appointment.
Contact soon if you notice
- Severe hypokalemia — can cause dangerous cardiac arrhythmias; monitor potassium regularly
- Hyponatremia (low sodium) — especially dangerous in elderly; can cause confusion, seizures, falls
- Acute kidney injury — usually from dehydration or combination with NSAIDs
- Photosensitivity — increased skin cancer risk with long-term use (FDA added warning)
- Blood pressure consistently above 140/90
Also discuss if you want to
- Review whether this medication is still appropriate for you
- Consider dosage adjustments based on response
- Explore lifestyle or non-drug alternatives
- Understand stopping or tapering options
- Plan monitoring labs and follow-up
In the US, call 911 or go to the nearest emergency room for severe symptoms. Poison Control: 1-800-222-1222.
Special Populations
Safety classifications for specific groups — discuss with your provider before use.
Can reduce placental perfusion. Not first-line for gestational hypertension. Labetalol or nifedipine preferred in pregnancy.
Excreted in breast milk in small amounts. May reduce milk production via volume depletion.
Used in pediatric hypertension; dosing based on weight. Monitor electrolytes carefully.
Preferred first-line in elderly per JNC guidelines. However, elderly are more susceptible to hyponatremia, dehydration, falls, and electrolyte disturbances. Start at 12.5mg.
Thiazides lose diuretic efficacy with declining kidney function. Below eGFR 30, loop diuretics (furosemide) are preferred.
FDA Adverse Event Reports
Patient-filed reports from the FDA FAERS database · refreshed daily
Community Reports
User-reported experiences — anonymous & anecdotal
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Stopping This Medication Safely
HCTZ does not cause physical dependence and can be stopped without pharmacological taper. Blood pressure will likely rise — the key question is whether lifestyle interventions can maintain control.
What Published Research Shows About Stopping This Medication
This summarizes what published research documents — it is not personal medical advice. Any changes to your medication require discussion with your prescribing physician.
- ·HCTZ itself can be stopped without tapering
- ·Blood pressure will likely rise within 1–2 weeks after stopping
- ·Implement lifestyle changes (DASH diet, exercise, sodium restriction) before or concurrent with stopping
- ·Monitor blood pressure at home daily for 2–4 weeks after stopping
- ·If BP remains elevated despite lifestyle changes, may need to restart or try alternative class
Warning Symptoms — Contact Your Doctor If You Experience:
- Blood pressure consistently above 140/90
- Headaches, visual changes, or chest pain (hypertensive urgency)
- Fluid retention or swelling
- Persistent headache
Never change or stop a medication without consulting your prescribing physician.
Questions for Your Doctor
Questions to Ask
- 1.Is HCTZ the right choice, or should I be on chlorthalidone (the drug actually studied in ALLHAT)?
- 2.Should I be taking a potassium supplement, or is my potassium being monitored?
- 3.Could dietary changes like the DASH diet reduce or replace my need for this medication?
- 4.Is HCTZ worsening my blood sugar or uric acid levels?
- 5.Do I need a higher dose, or should we add a second drug class instead?
Lab Tests to Request
- Basic metabolic panel (potassium, sodium, creatinine, glucose)
- Uric acid level (if gout history)
- Blood pressure log (home monitoring)
- HbA1c if diabetic or pre-diabetic
- Lipid panel annually
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Frequently Asked Questions About Hydrochlorothiazide (HCTZ)
- What is Hydrochlorothiazide (HCTZ) used for?
- Hydrochlorothiazide (HCTZ) (Hydrochlorothiazide) is a Thiazide Diuretic manufactured by Multiple generic manufacturers. FDA-approved indications include: Hypertension (first-line per JNC/ALLHAT); Edema (mild); Calcium nephrolithiasis prevention; Often combined with ACE inhibitors or ARBs.
- What are the common side effects of Hydrochlorothiazide (HCTZ)?
- Common side effects of Hydrochlorothiazide (HCTZ) include: Increased urination (15–20%); Dizziness / lightheadedness (8%); Hypokalemia (low potassium) (10–15%); Increased blood sugar (5–10%); Elevated uric acid / gout (5–8%).
- How much does Hydrochlorothiazide (HCTZ) cost?
- Hydrochlorothiazide (HCTZ) list price is approximately $5–20 (generic only). With insurance it typically costs $3–10; without insurance approximately $5–20.
- Who funded the clinical trials for Hydrochlorothiazide (HCTZ)?
- Uniquely among commonly prescribed cardiovascular medications, the most important HCTZ-class trials were publicly funded. ALLHAT — the largest antihypertensive trial ever conducted (42,000+ patients) — was funded by NHLBI (National Heart, Lung, and Blood Institute). It found that the thiazide diuretic chlorthalidone was as good as or better than more expensive calcium channel blockers and ACE inhibitors for preventing cardiovascular events. This was profoundly inconvenient for pharmaceutical companies selling expensive branded alternatives.
- How strong is the clinical evidence for Hydrochlorothiazide (HCTZ)?
- Key studies: ALLHAT (2002, NHLBI-funded), SHEP (1991, NIA/NHLBI-funded), Multiple VA studies. Reduces systolic BP 10–15 mmHg; ALLHAT showed thiazide-type diuretics prevent CV events as well as or better than newer, more expensive drug classes; 36% stroke reduction in SHEP Potential conflicts of interest: ALLHAT's conclusion that a cheap, generic diuretic was first-line therapy threatened billions in branded antihypertensive sales. Industry-funded trials subsequently promoted ACE inhibitors, ARBs, and .
- Are there non-drug alternatives to Hydrochlorothiazide (HCTZ)?
- HCTZ lowers blood pressure by reducing blood volume — it does not address why blood pressure is elevated. The primary modifiable drivers of hypertension are excess sodium intake, obesity (especially visceral fat), physical inactivity, excessive alcohol, chronic stress, and poor sleep. Lifestyle inte See the Alternatives tab for full details.
Get notified when we update Hydrochlorothiazide (HCTZ)
We'll email you when new evidence, safety updates, or alternatives are added.
No spam. Unsubscribe anytime.